Non-congenital severe ocular complications of Zika virus infection
Author(s) -
Mussaret B. Zaidi,
Carlos Gustavo De Moraes,
Michele Petitto,
Juan B. Yépez,
Anavaj Sakuntabhai,
Etienne SimonLorière,
Matthieu Prot,
Claude Ruffié,
Susan S. Kim,
Rando Allikmets,
Joseph D. Terwilliger,
Joseph H. Lee,
Gladys E. Maestre
Publication year - 2018
Publication title -
jmm case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.125
H-Index - 5
ISSN - 2053-3721
DOI - 10.1099/jmmcr.0.005152
Subject(s) - zika virus , principal (computer security) , clinical microbiology , quality (philosophy) , medicine , intensive care medicine , business , computer science , biology , virus , virology , microbiology and biotechnology , computer security , philosophy , epistemology
In 2016, during a major Zika virus (ZIKV) outbreak in Maracaibo, Venezuela, a 49-year-old woman and an unrelated 4-year-old boy developed bilateral optic neuritis 2–3weeks after presenting an acute febrile illness characterized by low-grade fever, rash and myalgia [1]. Both patients presented sudden, painless bilateral loss of vision with no corneal or uveal abnormalities. Fundoscopic examination revealed oedema of the optic nerve and optic disc pallor. Optical coherence tomography confirmed bilateral optic nerve head swelling in the case of the adult, but it was not carried out in the child. Automated perimetry performed in the adult revealed bilateral diffuse visual field loss. Magnetic resonance imaging of the brain in both cases was unremarkable. Both patients were diagnosed with bilateral optic neuritis of possible infectious or parainfectious origin. Differential diagnoses that were considered and subsequently discarded included arteritic and non-arteritic ischaemic optic neuropathy, and brain disorders such as multiple sclerosis and brain tumours. Both patients were seropositive for anti-ZIKV IgG and seronegative for anti-ZIKV IgM. In addition, both patients were positive for anti-dengue virus (DENV) IgG for all four DENV serotypes. Management included intravenous methylprednisolone for 3 days, followed by oral prednisolone for 11 days. Although the patients presented a modest improvement in their vision, they continued to have visual impairment after several months of follow-up [1]. DISCUSSION
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom